Product Program year 2025 Source: CMS Open Payments

Niktimvo

Drug Oncology

NDC 50881-012-10

Open in the dashboard

General payments

$1,113,403

4,185 payments

Research payments

$0

0 payments

Through program year 2025, $1,113,403 in general payments and $0 in research payments were reported against Niktimvo (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2025 General $1,102,138 4,162
2024 General $11,265 23

Breakdown

Who paid General payments · program years 2024–2025
  1. Incyte Corporation $1,113,403 4,185 payments
Top recipients General payments · program year 2025
  1. Usama Gergis Hematology & Oncology · Allentown, PA $99,719 9% · 99 payments
  2. Sam Penza Hematology · Columbus, OH $70,366 6% · 56 payments
  3. Sami Brake Medical Oncology · Grand Rapids, MI $66,896 6% · 78 payments
  4. Salman Fazal Hematology & Oncology · Pittsburgh, PA $65,555 6% · 70 payments
  5. George Yaghmour Hematology & Oncology · Los Angeles, CA $56,110 5% · 43 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Hematology & Oncology Internal Medicine $549,924 50% · 567 practitioners
  2. Hematology Internal Medicine $142,891 13% · 46 practitioners
  3. Medical Oncology Internal Medicine $115,060 10% · 135 practitioners
  4. Pediatric Hematology-Oncology Pediatrics $64,224 6% · 47 practitioners
  5. Nurse Practitioner, Adult Health Nurse Practitioner $46,860 4% · 96 practitioners

The top 5 of 61 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Pennsylvania $209,484 19% · 170 recipients
  2. California $189,867 17% · 233 recipients
  3. Ohio $135,108 12% · 84 recipients
  4. Texas $71,258 6% · 218 recipients
  5. Michigan $69,299 6% · 49 recipients

The top 5 of 51 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

4,185 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record